DOACs – advances and limitations in real world

The group of new oral anticoagulants or NOACs, now termed direct oral anticoagulants or DOACs, with their favourable results from large scale phase III clinical trials, represent a major advancement and expanded armamentarium in antithrombotic therapy. Dabigatran, rivaroxaban, apixaban and edoxaban...

Descripción completa

Detalles Bibliográficos
Autor principal: Lee, Lai Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056491/
https://www.ncbi.nlm.nih.gov/pubmed/27766043
http://dx.doi.org/10.1186/s12959-016-0111-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056491/
https://www.ncbi.nlm.nih.gov/pubmed/27766043
http://dx.doi.org/10.1186/s12959-016-0111-3

Ejemplares similares